Choosing a CRO is a decision about how your clinical program will operate:  how risks are identified, how sites are supported, how data and quality are managed, how quickly decisions are made, and whether the study can be delivered when the plan inevitably encounters reality.

That is why the “best” CRO is not automatically the largest, the most familiar, or the lowest-cost bidder.

The best CRO is the partner whose…

A company's first clinical trial is typically a leadership problem disguised as an operational one. The operational elements can be outsourced. The sponsor responsibilities cannot.

The most common misunderstanding is the scope of what remains with the sponsor after a CRO is engaged. Regulatory accountability does not transfer. Oversight obligations…

When a biotech company begins to move from discovery into clinical development, the leadership needs change quickly. Someone has to translate a scientific plan into an operational one, manage outside partners, and keep spending aligned with the capital runway. Many founders assume the only answer is a full-time Chief Operating Officer. Often, a fractional COO is the better first step.

Consider the math. A full-time COO with…

Clinical operations leaders are routinely accountable for budgets they were never taught to read. The result is a predictable pattern: a study runs over, the overage is attributed to enrollment challenges or scope evolution, and nobody can reconstruct which decisions actually caused it.

Financial fluency for a clinical leader does not require accounting expertise, but it does require a working grasp of four things…

Risk-based quality management asks clinical leaders to do something genuinely difficult: decide where not to look. A framework that concentrates oversight on the data and processes most critical to participant safety and trial reliability necessarily reduces attention elsewhere. That is why RBQM implementations so often stall.

The stall usually takes a recognizable form. The organization adopts the framework, builds the risk assessment, defines key risk indicators, configures the platform, and then continues monitoring everything at close to the previous intensity because…

Most emerging companies reach the same crossroads. The science is promising, the first-in-human study is on the horizon, and the board is asking who will own clinical execution. The answer is often nobody, at least not yet. Hiring a full-time Chief Operating Officer or VP of Clinical Operations can take six months and cost more than the company can justify before a financing milestone. That gap is exactly where fractional executive leadership earns its place.

A fractional executive is a seasoned leader who works with your company on a part-time or defined-scope basis. In clinical research, that usually means…

You can outsource execution. You cannot outsource accountability.

That distinction is where many CRO/sponsor partnerships succeed…or unravel.

For a small biotech, hiring a CRO can feel like acquiring a ready-made clinical operations organization, but a CRO is not a substitute for a sponsor-side operating model.

The sponsor still owns…

Competency frameworks in clinical research tend toward two failure modes. They are either so generic they describe any manager in any industry, or so exhaustive that nobody reads them after the first assessment cycle.

A useful framework for clinical project managers is narrow, observable, and tied to actual study work. Five domains cover most of what matters.

Operational planning is the…

A well-written MSA and SOW do not manage CRO performance.

They establish the commercial and contractual foundation. But when timelines slip, enrollment assumptions change, site activation stalls, or a critical issue sits unresolved, the contract is rarely what determines the outcome.

Governance does.

Too many sponsors over-index on…

If your governance model produces 12 pages of meeting minutes, but no clear decision, owner, or change in course, it is not operational oversight.  It might be compliance theater.

As organizations implement ICH E6(R3), I worry that some will respond as our industry often does to change: add another meeting, expand the checklist, build another dashboard, and document every discussion in greater detail.

But R3 is not a mandate to create…

More sponsor oversight does not automatically create better CRO oversight or operational excellence.

In biotech, uncertainty often triggers more meetings, trackers, dashboards, action logs, and approval layers. It can feel like control. But it can also create administrative drag while the operational risks most likely to affect patients, data quality, timelines, and delivery receive the same attention as everything else.

A risk-based oversight model asks a more useful question…

Turnover in clinical operations, particularly among clinical research associates and clinical trial managers, remains a persistent constraint on delivery. It disrupts site relationships, erodes study knowledge, and imposes retraining costs that never appear cleanly in a budget line.

Compensation drives some of it and leaders control little of that directly. Several other drivers are within reach.

Workload opacity ranks…

Many biotech and emerging biopharma sponsors are treating ICH E6(R3) as a documentation update:  new templates, new signatures, same relationship with the CRO underneath. That reading will not survive an inspection. R3 says accountability cannot be delegated. Whatever the CRO does, the sponsor still owns trial quality and participant safety, and a CRO's failure shows up as the sponsor's finding.

That changes three things that are currently on autopilot…

On June 3, 2026, the final ICH E6(R3) Good Clinical Practice Annex 2 was adopted and officially published by the International Council for Harmonisation.

With Annex 1 already moving into implementation, Annex 2 completes the updated global GCP framework. And for biotech and emerging biopharma, this is a signal that the operating model for clinical research must evolve…

For lean biotech and emerging biopharma teams, ICH E6(R3)’s risk-based approach is an invitation to spend deliberately. You do not need to monitor every site, data point, activity, and process with the same intensity. The goal is proportionality.  To focus oversight where failure could genuinely compromise participant safety, rights, wellbeing, or the reliability of the data needed to make a development decision.

A proportional monitoring plan starts with…

Artificial intelligence is already reshaping parts of clinical operations. Site identification, enrollment forecasting, risk signal detection, document drafting, and query generation are all being automated or augmented. The question for clinical leaders is which parts of their role this touches.

The work that compresses is largely the synthesis and monitoring layer. Producing a status summary from multiple system exports, identifying outlier sites from monitoring data, drafting a first version of a study plan, and scanning for protocol deviation patterns are all tasks where a capable model plus a competent reviewer outperforms the manual process on speed and often on coverage. Leaders who spend…